Rosetta Stone 2013 Annual Report Download - page 70
Download and view the complete annual report
Please find page 70 of the 2013 Rosetta Stone annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60 -
61 -
62 -
63 -
64 -
65 -
66 -
67 -
68 -
69 -
70 -
71 -
72 -
73 -
74 -
75 -
76 -
77 -
78 -
79 -
80 -
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
 |
 |
Table of Contents
(As Adjusted)*
(As Adjusted)*
Net loss
$(16,134)
$(33,985)
$(19,650)
Adjustments to reconcile net loss to cash provided by operating activities:
Stock-based compensation expense
9,241
8,009
12,353
Bad debt expense
1,420
1,820
1,228
Depreciation and amortization
9,635
8,077
8,724
Deferred income tax (benefit) expense
(3,869)
25,953
(1,086)
Loss on disposal of equipment
278
783
318
Net change in:
Restricted cash
(37)
1
11
Accounts receivable
(9,477)
309
(5,058)
Inventory
(108)
185
3,168
Prepaid expenses and other current assets
(3,511)
1,165
110
Income tax receivable
827
6,515
(5,812)
Other assets
(1,680)
166
(25)
Accounts payable
3,702
(1,240)
(447)
Accrued compensation
(897)
5,093
1,200
Other current liabilities
4,250
635
3,979
Excess tax benefit from stock options exercised
—
—
(365)
Other long term liabilities
481
(99)
(52)
Deferred revenue
13,947
11,514
4,777
Net cash provided by operating activities
8,068
34,901
3,373
Purchases of property and equipment
(8,941)
(4,187)
(9,940)
Proceeds from sales (purchases) of available-for-sale securities
—
9,711
(3,301)
Increase in restricted cash related to Vivity Labs acquisition
(12,314)
—
—
Acquisitions, net of cash acquired
(25,675)
—
(75)
Net cash (used in) provided by investing activities
(46,930)
5,524
(13,316)
Proceeds from the exercise of stock options
2,457
862
800
Repurchase of shares from exercised stock options
(1,040)
—
—
Purchase of treasury stock
(11,435)
—
—
Tax benefit of stock options exercised
—
—
365
Proceeds from equity offering, net of issuance costs
(228)
—
—
Payments under capital lease obligations
(241)
(215)
(285)
Net cash (used in) provided by financing activities
(10,487)
647
880
(Decrease) increase in cash and cash equivalents
(49,349)
41,072
(9,063)
Effect of exchange rate changes in cash and cash equivalents
(16)
602
(177)
Net (decrease) increase in cash and cash equivalents
(49,365)
41,674
(9,240)
Cash and cash equivalents—beginning of year
148,190
106,516
115,756
Cash and cash equivalents—end of year
$98,825
$148,190
$106,516
Cash paid during the periods for:
Interest
$18
$—
$5
Income taxes
$3,290
$ 4,040
$1,683
Noncash financing and investing activities:
Accrued purchase price of business acquisition
$3,375
$—
$—
Accrued liability for purchase of property and equipment
$192
$1,228
$204
Equipment acquired under capital lease
$702
$—
$ 16
See accompanying notes to consolidated financial statements
* Certain amounts have been adjusted for the retrospective change in accounting principle for sales commissions (See Note 3)